However, while DFG-out Raf inhibitorssuch as the multikinase inhibitor sorafenib are already in daily usefor the treatment of HCC patients, specific LXRα agonists arenot applicable in the clinic so far.7 Consequently,the development of specific LXRα activating ligands is a prerequisitefor bringing this promising therapeutic approach into clinical use. Here, RAF1 is linked to hepatocellular carcinoma.